Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lotus Tissue Repair

Request full access

Recombinant collagen protein therapy for treating orphan diseases

Cambridge, United StatesFounded 2010Biotech & Life Sciences

About Lotus Tissue Repair

Lotus Tissue Repair was a biotechnology company focused on developing a protein replacement therapy for the rare genetic skin disorder, Dystrophic Epidermolysis Bullosa (DEB). Founded in 2011, the company was the result of a collaboration between biotechnology entrepreneurs and scientific experts, backed by the life sciences investor Third Rock Ventures. The founding team included Dr. Mark de Souza as CEO, along with co-founders James Fordyce and Dr. Philip Reilly. The core technology was licensed from the University of Southern California (USC) and was based on the groundbreaking research of professors Dr. Mei Chen and Dr. David Woodley, who became scientific co-founders of the company. Their work centered on a proprietary recombinant form of human collagen Type VII (rC7), a protein crucial for skin integrity.

The company's lead program aimed to provide the first-in-class systemic therapy for DEB, a severe and painful condition characterized by extremely fragile skin and recurrent blistering for which only palliative care was available. The rC7 protein replacement therapy was designed to be administered intravenously, directly addressing the underlying deficiency of functional collagen VII that causes the disease. Preclinical studies showed that the therapy was potent, long-lasting, and specifically targeted wounded skin. In June 2011, Lotus Tissue Repair secured $26 million in a Series A financing round to advance its lead product candidate, which was in late-stage preclinical development.

In January 2013, the company was acquired by Shire plc (now part of Takeda Pharmaceutical Company). The acquisition included an upfront payment and future contingent payments based on development and safety milestones. Shire's Human Genetic Therapies business unit took over the continued development of the rC7 therapy, integrating it into its portfolio of treatments for rare diseases.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
53.4/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Tissue Engineering, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B, B2C

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2011 $26M $104M Third Rock Ventures —
SPINOUT✓Other financing Jan 2010 $0 — University of Southern California —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Lotus Tissue Repair website traffic

Latest recorded traffic for Lotus Tissue Repair is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lotus Tissue Repair in the Cambridge ecosystem

Live from Dealroom

The Lotus Tissue Repair office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Other known investors1 additional known investor

  • University of Southern California
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lotus Tissue Repair on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lotus Tissue Repair’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.